Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma

Alessandro Leonetti
Francesco Leonardi
Melissa Bersanelli
Sebastiano Buti
Medical Oncology Unit, University Hospital of Parma, Parma, Italy

Introduction: Renal cell carcinoma (RCC) represents 2%–3% of all cancers in adults, and its pathogenesis is mainly related to altered cellular response to hypoxia. Lenvatinib, a novel multitarget tyrosine kinase inhibitor (TKI), represents a therapeutic option, in combination with mammalian target of rapamycin (mTOR) inhibitor everolimus, for the treatment of metastatic RCC (mRCC).

Aim: The objective of this article is to review the evidence about the treatment of mRCC with combination of lenvatinib plus everolimus.

Evidence review: Phase I studies supported clinical activity of lenvatinib in mRCC. A randomized, Phase II, open-label, multicenter trial demonstrated the clinical efficacy of combination treatment with lenvatinib plus everolimus in patients with progressive mRCC after prior therapy with TKI. Median progression-free survival was improved by 9 months with the combination therapy compared to the single-agent everolimus, with an overall response rate of 43% for the experimental regimen. Lenvatinib plus everolimus appeared to be slightly less toxic than single-agent lenvatinib and more toxic than single-agent everolimus; grade 3–4 adverse events occurred in 71% of patients. Currently, lenvatinib plus everolimus has US Food and Drug Administration approval for its use in mRCC after failure of previous treatment with TKI.

Conclusion: The combination therapy with lenvatinib plus everolimus might be a promising choice for second-line treatment of mRCC patients. Based on the results of the Phase II trial, it is possible to speculate that the combination therapy could be appropriate for patients with high disease burden or strongly symptomatic patients.

Keywords: lenvatinib, everolimus, evidence-based review, renal cell carcinoma, RCC

Introduction

Renal cell carcinoma (RCC) represents 2%–3% of all cancer, and its incidence has increased by ~2% worldwide over the two last decades. The most common histotype is represented by clear cell RCC (ccRCC), accounting for 70%–85% of sporadic RCC; less frequent variants include papillary (7%–15%) and chromophobe RCC (5%–10%). RCC is often diagnosed incidentally when undergoing abdominal imaging for other reasons, and it occurs as metastatic disease at diagnosis in about one third of patients. Usually, surgery is the initial treatment for both local and locally advanced disease; however, for most patients with advanced tumor, systemic therapy is needed.

Recent advances in the understanding of tumor biology and of pathogenetic mechanisms have led to the development of new drugs for the management of metastatic disease, including new targeted therapies, such as tyrosine kinase inhibitors (TKIs), mammalian target of rapamycin (mTOR) inhibitors, and programmed death-1 (PD-1)
programmed death ligand-1 (PD-L1) immune checkpoint inhibitors.6

TKIs are small molecules that inhibit key pathways involved in RCC cell growth and proliferation, cellular metabolism, and angiogenesis, such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and mTOR pathways. Until recently, four TKIs were available for the treatment of metastatic RCC (mRCC): sunitinib, which targets VEGF and PDGF receptors (VEGFR and PDGFR, respectively), c-KIT, and FMS-like tyrosine kinase-3 (FLT-3);7 pazopanib, a selective inhibitor of VEGFRs, PDGFR, and c-KIT;8 axitinib, which inhibits VEGFR-1, VEGFR-2, and VEGFR-3;9 and sorafenib, a multi-inhibitor of Raf-1 serine/threonine kinase, BRAF, VEGFR-2, PDGFR, FLT-3, and c-KIT.10 According to current European Society of Medical Oncology guidelines, sunitinib and pazopanib are recommended for the first-line treatment of recurrent, metastatic, or inoperable RCC with good–intermediate prognosis; axitinib and sorafenib are approved for their use after failure of first-line therapy. Interferon-α plus bevacizumab, an anti-VEGF-A monoclonal antibody, represent another option for the management of mRCC with good–intermediate prognostic features in first-line setting. Among mTOR inhibitors, temsirolimus and everolimus have shown activity in mRCC: temsirolimus is recommended for the first-line treatment of poor prognosis ccRCC or non-ccRCC, whereas everolimus is a treatment option for second and subsequent lines.2

Until recently, the standard treatment for advanced ccRCC after first-line TKI failure was represented by axitinib or everolimus; sorafenib was reserved only for selected cases. Two new molecules, cabozantinib and nivolumab, have shown superiority over everolimus in terms of overall survival (OS) and response rate (RR) in second-line setting for mRCC in two comparative head-to-head Phase III trials.11,12 Based on these results, cabozantinib and nivolumab are preferred choices over everolimus in second-line therapy.2,13

Lenvatinib (E7080, Lenvima®; Eisai, Hatfield, UK) is a multistarget kinase inhibitor firstly approved by US Food and Drug Administration (FDA) and European Medicine Agency (EMA) as monotherapy for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer, and more recently approved by FDA, in combination with everolimus, for the treatment of advanced RCC following one prior antiangiogenic therapy. This review discusses the mechanism of action, pharmacokinetics, clinical efficacy, and tolerability of lenvatinib in combination with everolimus for the treatment of advanced RCC.

Mechanism of action

Two pivotal molecular events are involved in the pathogenesis of ccRCC: the loss of function of von Hippel–Lindau (VHL) gene that acts as a tumor-suppressor gene and the consequent overexpression of hypoxia-inducible factors (HIF). The protein encoded by VHL gene is responsible for HIF expression downregulation by degrading HIF-1α subunit. The reduced activity of VHL gene results in constitutively activated hypoxic response even in the absence of a hypoxic signal,14 leading to the transcription of HIF-responsive genes, such as VEGF, PDGF, and transforming growth factor beta (TGF-β).15 This event is crucial in RCC carcinogenesis; overexpressed growth factors induce pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions.16

The second critical pathway involved in the development and growth of RCC is regulated by mTOR protein. The mTOR signaling pathway is known to be responsible for anchorage-independent cellular expansion, increased proliferative potential and evasion from apoptosis, and increased cell motility and metastasis.17 Moreover, the activation of mTOR induced by overexpressed growth factors (ie, VEGF and PDGF) promotes HIF expression,18,19 triggering a positive feedback loop between VHL/HIF and mTOR signaling.20 It is evident that the two pathways are closely connected and cross-talking, hence the attempt of combining both TKI and the mTOR inhibitors for the treatment of mRCC.

In the past, randomized trials have been conducted trying to combine VEGF and mTOR inhibitors, with poor results on efficacy outcomes and increased drug toxicity. Combinations of temsirolimus plus bevacizumab, temsirolimus plus sorafenib, and everolimus plus bevacizumab were also investigated, with disappointing results.21–23

Lenvatinib is a novel potent multitarget TKI that performs its action through the inhibition of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-β, RET, c-KIT, and fibroblast growth factor receptors (FGFR) 1–4, the latter deemed as responsible for resistance to VEGF inhibitors in RCC.24,25 Preclinical data on the effect of the combination of lenvatinib with everolimus have been reported. Matsumi et al investigated the mechanisms of these drugs used in combination in human RCC xenograft mouse models: everolimus demonstrated antiproliferative effects, whereas lenvatinib showed antiangiogenic properties. In this study, tumor angiogenesis was evaluated by microvessel density (MVD) of the tumor; whereas lenvatinib monotherapy consistently reduces MVD.
in A-498 xenografts, everolimus monotherapy did not. In the same xenograft model, enhanced antitumor activity resulted from the combination of the two drugs, suggesting the synergistic effect of the two different mechanisms of action.

It is evident that targeting tumor cell growth and angiogenesis through the combination of lenvatinib plus everolimus can result in enhanced antitumor activity.Enhanced antitumor activity resulted from the combination of the two drugs, suggesting the synergistic effect of the two different mechanisms of action.

A strong rationale to combine two molecules with different mechanism of action (Figure 1), the good tolerability profile of everolimus in mRCC patients and the availability of preclinical data that showed the synergistic antitumor effect of these two drugs, all together are elements that justify the choice to further develop the combination of everolimus (instead of other agents) with lenvatinib in the clinical setting.

**Pharmacokinetics**

Lenvatinib is orally administered. The peak of its concentration ($C_{\text{max}}$) is reached within 3 hours from administration and it increases linearly with dose increase, as observed in two Phase I dose–escalation studies investigating pharmacokinetics of the drug administered at escalation doses of 0.2 mg up to 32 mg per day and 0.5 mg bid up to 20 mg bid. No accumulation after multiple once-daily dose was observed. In subjects with adequate renal and hepatic function, $C_{\text{max}}$ and systemic exposure (as measured by area under the curve [AUC]) do not vary under fasting conditions (AUC ratio fed/fasted of 1.00 [90% confidence interval {CI} 0.82–1.20]; $C_{\text{max}}$ ratio fed/fasted of 0.98 [90% CI 0.73–1.31]), but an effect of food on time to maximal plasma concentration ($t_{\text{max}}$) was observed, with a shift from 2 hours in the fasted group to 5 hours in the fed group, resulting in delayed absorption following a standard high-fat meal. The terminal volume of distribution of orally administered lenvatinib varies from 50.5 to 163 L, and terminal half-life ($t_{1/2}$) is ~28 hours.

Lenvatinib is highly bound to plasma proteins and metabolized into many metabolites, mainly in the liver; low levels of unchanged lenvatinib were found in urine and feces.

The principal isozyme of cytochrome involved in hepatic metabolism of lenvatinib is CYP3A4, which is responsible for >80% of the CYP-mediated metabolism of the drug.
Two drug-interaction studies by Shumaker et al have been conducted to test the pharmacokinetic parameters of lenvatinib when coadministered with CYP3A4 or P-gp inhibitors (rifampicin and ketoconazole, respectively). Lenvatinib exposure was increased by CYP3A4 or P-gp inhibition, but the magnitude of change was not clinically meaningful.32,33 

Pharmacokinetics was studied also in special populations. The average AUC of lenvatinib in 12 subjects with mild or moderate hepatic impairment increased by 170% compared to the AUC found in eight healthy volunteers, and \( t_{1/2} \) increased from 23 to 37 hours, suggesting dose adjustments for patients with hepatic dysfunction.34 Impaired renal function and the concomitant administration of everolimus in patients affected by mRCC seem to not affect the pharmacokinetic properties of lenvatinib. When lenvatinib was administered at a dose of 18 mg in combination with everolimus 5 mg, oral clearance and volume of distribution as a function of bioavailability did not vary compared to lenvatinib 24 mg; AUC of lenvatinib 28 mg in combination with everolimus 5 mg, dose-normalized to 24 mg, was similar to the AUC of single-agent lenvatinib at a dose of 24 mg.29,35 

### Clinical efficacy and safety

Clinical trials of efficacy and safety of lenvatinib alone or in combination with everolimus in advanced RCC are shown in Table 1.

#### Phase I evidence

Preliminary evidence of antitumor activity of lenvatinib in patients with advanced solid tumors was provided by a Phase I, dose–escalation study by Yamada et al. Twenty-seven patients affected by different histological types of solid tumors, refractory to conventional therapies or for which there was no available effective therapy, were treated with

![Table 1 Clinical trials of efficacy and safety of lenvatinib in renal cell carcinoma](https://www.dovepress.com/)

<table>
<thead>
<tr>
<th>Clinical trial</th>
<th>Design</th>
<th>Arms</th>
<th>Efficacy</th>
<th>Safety</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boss et al38</td>
<td>Phase I, dose–escalation, multicenter, open-label</td>
<td>Lenvatinib, starting from 0.2 mg daily</td>
<td>mPFS (for RCC patients): 447 days</td>
<td>Most common AEs: diarrhea (45%), nausea (37%), proteinuria (26%), hypertension (23%), and vomiting (23%)</td>
</tr>
<tr>
<td>n=20</td>
<td></td>
<td></td>
<td>ORR: 35%</td>
<td>Grade 3 AEs: hypertension (11%) and proteinuria (7%)</td>
</tr>
<tr>
<td>mRCC patients =9</td>
<td></td>
<td></td>
<td>Overall population: 55%</td>
<td>Grade 4 AEs: thrombocytopenia (2%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>mRCC patients: 4/9 PR</td>
<td></td>
</tr>
</tbody>
</table>

| Molina et al34 | Phase I, dose–escalation, multicenter, open-label | Lenvatinib plus everolimus | Cohort 1 and 2: mPFS: 330 days | Most common AEs: fatigue (60%), mucosal inflammation (50%), diarrhea (40%), hypertension (40%), nausea (40%), proteinuria (40%), and vomiting (40%) |
| n=20 |       |       | 6-month PFS rate: 72.1% | Grade 3–4 AEs: hypertension (15%), proteinuria (15%), diarrhea (10%), and fatigue (10%) |
| Patients with prior anti-VEGF treatment =17 |       |       | 12-month PFS rate: 49.5% | |
| Patients with prior mTOR-targeted therapy =7 |       |       | All cohorts: DCR: 80% | |

| Motzer et al35 | Phase II, randomized, multicenter, open-label | Lenvatinib 18 mg plus everolimus 5 mg daily (n=51) | mPFS: Lenvatinib plus everolimus: 14.6 months | Discontinuation due to AEs: Lenvatinib plus everolimus: 24% |
| n=153 mRCC patients who progressed after 1 prior TKI | | Lenvatinib 24 mg daily (n=52) | Lenvatinib alone: 7.4 months | Lenvatinib alone: 25% |
| | | Everolimus 10 mg daily (n=50) | Everolimus alone: 5.5 months | Everolimus alone: 12% |
| | | | ORR: Lenvatinib plus everolimus: 43% | Any grade AEs: 100% |
| | | | Lenvatinib alone: 27% | Grade 3 or 4 AEs: |
| | | | Everolimus alone: 6% | Lenvatinib plus everolimus: 71% |
| | | | mOS (updated analysis) | |
| | | | Lenvatinib plus everolimus: 25.5 months | Lenvatinib alone: 79% |
| | | | Everolimus alone: 19.1 months | Everolimus alone: 50% |
| | | | | |

**Abbreviations:** VEGF, vascular endothelial growth factor; mTOR, mammalian target of rapamycin; mPFS, median progression-free survival; ORR, objective response rate; PFS, progression-free survival; PR, partial response; DCR, disease control rate; mOS, median overall survival; mRCC, metastatic renal cell cancer; TKI, tyrosine kinase inhibitor; AE, adverse event; n, number of patients.
oral lenvatinib in a 2-week-on/1-week-off cycle, starting from a dose of 0.5 mg bid, to assess the maximum tolerated dose (MTD). The MTD was determined to be 13 mg bid, and observed dose-limiting toxicities (DLTs) included grade 3 aspartate aminotransferase/alanine aminotransferase increase and grade 3 platelet count decrease, according to Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Twenty-one patients (84%) demonstrated stable disease (SD) as their best response to treatment, and one patient affected by metastatic colon cancer showed partial response (PR).²⁷

A subsequent non-randomized, open-label, Phase I, dose-escalation study supported clinical activity of lenvatinib in mRCC. Eighty-two patients affected by different histological types of solid tumors were enrolled. Lenvatinib was given on a continuous once-daily administration schedule. One cycle of treatment consisted of 28 days, and dose escalation was allowed after each cycle, starting from a dose of 0.2 mg per day. The MTD was determined to be 25 mg per day, and the most common adverse events (AEs) of any CTCAE version 3.0 grade included diarrhea (45%), hypertension (40%), nausea (37%), stomatitis (32%), proteinuria (26%), and vomiting (23%). Grade 3 hypertension and grade 3 proteinuria occurred in 11% and 7% of the overall population, respectively. Grade 4 thrombocytopenia was documented in 2% of patients. Seven patients (9%) showed PR and 38 patients (46%) displayed SD as their best response. Among the population affected by mRCC (n=9 [11%]), four patients achieved a PR. In this cohort, the reported median progression-free survival (mPFS) was 447 days (95% CI 279.0–559.0), and the extent of tumor reduction ranged from 5% (with lenvatinib 3.3 mg) to 55% (with lenvatinib 25 mg).²⁸

The combination of lenvatinib plus everolimus for the treatment of mRCC progressed after VEGF-targeted therapy was first tested in a Phase Ib trial. Twenty patients were treated in sequential cohorts of escalating doses, starting from lenvatinib 12 mg plus everolimus 5 mg once daily (cohort 1), and increasing to lenvatinib 18 mg plus everolimus 5 mg once daily (cohort 2) up to lenvatinib 24 mg plus everolimus 5 mg once daily (cohort 3). Dose escalation was admitted after a 28-day treatment cycle without DLTs. The MTD was determined to be lenvatinib 18 mg plus everolimus 5 mg once daily, and the median number of treatment cycles was 5.5. The most common AEs of any grade were fatigue (60%), mucosal inflammation (50%), diarrhea (40%), hypertension (40%), nausea (40%), proteinuria (40%), and vomiting (40%). Grade 3–4 toxicities were documented in 15/20 patients (75%) and they included hypertriglyceridemia (15%), proteinuria (15%), diarrhea (10%), and fatigue (10%). Thirty percent of all patients had a PR as their best response (95% CI 11.9–54.3), and disease control rate was achieved in 80% of patients across all cohorts. In cohorts 1 and 2, the mPFS was 330 days (95% CI 157–446); 6-month and 12-month PFS rates were 72.1% (95% CI 48.8–95.4) and 49.5% (95% CI 22.7–76.2), respectively.²⁹

**Phase II evidence**

Consequent to the encouraging results of Phase I studies, a randomized, Phase II, open-label, multicenter trial by Motzer et al explored efficacy and safety of second-line treatment with lenvatinib alone or in combination with everolimus, compared to single-agent everolimus in the setting of mRCC. PFS was the primary endpoint, while toxicity, objective RR, and OS were secondary endpoints. One hundred and fifty-three patients with advanced ccRCC who progressed after one prior VEGF-targeted therapy were randomized 1:1:1 to receive single-agent lenvatinib (24 mg daily), single-agent everolimus (10 mg daily), or the combination (lenvatinib 18 mg plus everolimus 5 mg daily) in 28-day continuous cycles. Median treatment duration was 7.6 months for patients receiving the combination of both drugs, 7.4 months for those allocated to single-agent lenvatinib, and 4.1 months for those included in the single-agent everolimus arm.

Regarding the primary endpoint, mPFS was significantly improved by the combination therapy compared to single-agent everolimus (14.6 vs 5.5 months; hazard ratio [HR]: 0.40; 95% CI 0.24–0.68; P=0.0005). Single-agent lenvatinib also increased mPFS compared to single-agent everolimus (7.4 vs 5.5 months; HR: 0.61; 95% CI 0.38–0.98; P=0.048). However, there was no statistically significant difference in terms of mPFS between the combination treatment and lenvatinib alone (HR: 0.66; 95% CI 0.39–1.10; P=0.12), despite a favorable trend.³⁵ Notably, the benefit in terms of PFS was confirmed by a blinded independent radiologic assessment.³⁷

Overall response rate (ORR) was 43% for patients receiving the combination therapy, compared to 6% for patients treated with everolimus alone (rate ratio 7.2; 95% CI 2.3–22.5; P<0.0001); ORR was 27% for the single-agent lenvatinib arm, but data compared to those of the combination arm were not statistically significant (rate ratio 1.6; 95% CI 0.9–2.8; P=0.10). Conversely, the difference in terms of ORR between single-agent lenvatinib and single-agent everolimus was relevant and significant (rate ratio 4.5; 95% CI 1.4–14.7; P=0.0067). Increase in median OS (mOS) for the combination arm was not significant at a primary data cutoff.
of the study, whereas the post hoc updated analysis showed an mOS of 25.5 months for lenvatinib plus everolimus, of 19.1 months for single-agent lenvatinib, and of 15.4 months for single-agent everolimus. In this updated analysis, the increase of mOS for the combination compared to single-agent everolimus was statistically significant (25.5 vs 15.4 months; HR: 0.51, 95% CI 0.30–0.88; P=0.024). Nevertheless, mOS did not statistically differ between the single-agent lenvatinib arm and everolimus alone arm (19.1 vs 15.4 months; HR: 0.68; 95% CI 0.41–1.14; P=0.12) or combination arm (25.5 vs 19.1 months; HR: 0.75, 95% CI 0.43–1.30; P=0.32).

In all, 71% of patients receiving lenvatinib plus everolimus and 62% of those assigned to lenvatinib alone required a lenvatinib dose reduction due to AEs. No unexpected drug toxicities were reported. The most frequently reported events were consistent with the class-specific AEs of the two molecules; treatment discontinuation due to AEs was observed in 24% of patients allocated to the lenvatinib plus everolimus arm, 25% of patients who received lenvatinib, and 12% of patients assigned to everolimus. Grade 3–4 AEs occurred in 71% of patients receiving the combination, 79% for single-agent lenvatinib, and 50% for single-agent everolimus. Among these, the most common were diarrhea, fatigue, and hypertension for the first treatment arm; proteinuria, hypertension, and diarrhea for the second one; anemia, dyspnea, hypertriglyceridemia, and hyperglycemia for the third one.

Only one case of fatal drug-related AE (cerebral hemorrhage) was reported in the combination treatment arm; in the single-agent lenvatinib arm, one of three deaths due to AEs was supposed to be drug-related (myocardial infarction); no death in the single-agent everolimus arm was considered to be treatment-related.

Unfortunately, quality of life was not investigated in this study.35 Considering the positive results of the Phase II trial, lenvatinib received US FDA approval on May 13, 2016 for the treatment of advanced RCC after failure of prior TKI therapy at the dose of 18 mg/daily in combination with everolimus 5 mg/daily. The application for the EMA approval was announced by Eisai Co, Ltd in January 2016.38

Discussion
In Phase I and Phase II trials, lenvatinib has shown significant antitumor activity in mRCC, and the combination of lenvatinib plus everolimus seems to be more effective than single-agent therapy. Lenvatinib is the only TKI which showed promising and relevant preclinical and clinical efficacy in combination with an mTOR inhibitor for the treatment of mRCC, with an acceptable toxicity profile.

The pivotal Phase II trial conducted by Motzer et al met its primary endpoint, mPFS, which is considered as a reasonable measure of outcome for a Phase II study. The trial was designed to have 70% power to detect a 50% improvement (HR 0.67) in PFS at a one-sided alpha level of 0.15 of the combination of the two drugs or single-agent lenvatinib compared to single-agent everolimus, assuming an mPFS of 5 months for everolimus and 7.5 months for each lenvatinib-containing arm. The mPFS was improved by 9 months with the combination therapy compared to everolimus, with an HR significantly lower than preestablished (14.6 vs 5.5 months; HR: 0.40; 95% CI 0.24–0.68; P=0.0005).35 The independent radiologic assessment confirmed benefit in terms of PFS, strengthening the positive result.37 Moreover, outcome results of the control arm with single-agent everolimus were consistent with those obtained in previous studies investigating everolimus in second-line setting for mRCC after failure of previous TKIs, in terms of PFS, ORR, and OS.11,12,39 Regarding secondary endpoints, ORR was broadly larger for the combination regimen (43% vs 27% for single-agent lenvatinib and 6% for single-agent everolimus); OS also improved by the association of the two drugs, even if the result was not significant at primary data cutoff. Of note, patients enrolled in the study had overall characteristics similar to real life population, with a considerable portion of poor-risk patients (39% according to the Memorial Sloan–Kettering Cancer Center risk status).35 Despite promising results on efficacy outcomes, the combination treatment appeared more toxic than single-agent everolimus, despite being no more toxic than single-agent lenvatinib, with a not-negligible incidence of grade 3–4 AEs (71%) and one reported case of fatal drug-related event in the combination arm, suggesting the need for optimization in the monitoring and treatment of AEs. The different toxicity profile of lenvatinib between the two arms may be due to the full dose administered in the single-agent arm (24 mg) versus the reduced dose of the combination arm (18 mg). Of note, no unexpected treatment-related AEs were observed.35 Based on all these findings, with the limits of a Phase II open-label study, it is acceptable to consider these results as very relevant for their possible application in clinical practice.13

Moreover, the results of this randomized study clearly suggest that maintaining the suppression of VEGF pathway (“VEGF pressure”) could represent a good therapeutic strategy after failure of first-line TKI treatment; in addition, the simultaneous blockade of the mTOR pathway seems to be
definitely more efficient. The value of the “VEGF pressure” theory is further supported by the results of the METEOR study, a randomized Phase III trial in which cabozantinib, a novel TKI, obtained a better PFS than those of everolimus in mRCC patients who progressed after ≥1 prior TKIs (7.4 vs 3.8 months; HR: 0.51, 95% CI 0.41–0.62; P=0.0001).11

Indeed, this cited trial currently represents the first and only controlled study with a direct comparison between the treatment sequence “TKI-mTOR inhibitor” and a “TKI-TKI strategy”, the latter coming out as the winner.

Recently, the anti-PD-1 antibody nivolumab was approved by FDA and EMA for the treatment of mRCC in second-line setting. The pivotal trial CheckMate-025 showed an mOS improvement for patients who received nivolumab compared to those treated with everolimus (25.0 vs 19.6 months; HR: 0.75, 95.5% CI 0.57–0.93; P=0.002) with no significant difference in terms of mPFS (4.6 months for nivolumab vs 4.4 months for everolimus; HR: 0.88, 95% CI 0.75–1.03; P=0.11). This interesting finding has aroused hopes and has opened a new landscape for the treatment of mRCC, but on the other hand risking to obscure the value of a proven targeted therapy strategy, valuable at least for that fraction of patients primary refractory to immunotherapy (35% in CheckMate-025 study).12 One of the next challenges will be identification of adequate predictive factors that could help the clinician to choose the best therapy/strategy (ie, TKI-TKI-nivolumab sequence vs TKI-nivolumab-TKI sequence vs TKI-TKI-TKI/mTOR inhibitor sequence vs TKI-TKI+mTOR-nivolumab sequence) for each patient. Until then, the high ORR obtained with lenvatinib plus everolimus combination (43%) could suggest that patients with high disease burden or strongly symptomatic patients may be those most likely to benefit from this option.

Currently, a randomized, Phase III, three-arm trial is ongoing to compare the efficacy and safety of lenvatinib plus everolimus or of lenvatinib plus pembrolizumab versus sunitinib in first-line setting.41 The combination of lenvatinib plus everolimus is also being investigated in treatment-naive advanced non-cCRCC, in an ongoing Phase II trial.42

Conclusion

The combination therapy with lenvatinib plus everolimus is a promising choice for the treatment of mRCC patients who progress after first-line TKI treatment. It has been approved by the US FDA in this setting. Currently, use of either nivolumab or cabozantinib represents the new standard treatment in second-line setting; axitinib, everolimus, and sorafenib are still alternative options for selected patients.

Despite a not-negligible toxicity, lenvatinib plus everolimus showed improvement in PFS and high ORR; based on these findings, the combination therapy could be appropriate for patients with high disease burden or strongly symptomatic patients. Eventually, a Phase III study is needed to validate the encouraging results of the Phase II trial.

Disclosure

The authors report no conflicts of interest in this work.

References


